Hirsch H H, Steffen I, Francioli P, Widmer A F
Institut für Medizinische Mikrobiologie, Universität Basel.
Praxis (Bern 1994). 2006 Jan 18;95(3):61-6. doi: 10.1024/0369-8394.95.3.61.
RSV infections are an annually recurring problem of significant morbiditiy and mortality in the immunocompromised host, especially after lung and stem cell transplantation. The effectiveness of hygienic (isolation) and therapeutic (ribavirin, immunoglobulin, pavilizumab) measures depends of high index of suspicion and rapid diagnostic confirmation by the antigen test, PCR and/or culture. Allocation of resources require stratification of measures according to the known or estimated risk for complications.
呼吸道合胞病毒（RSV）感染是免疫功能低下宿主每年都会出现的一个问题，会导致严重的发病率和死亡率，尤其是在肺移植和干细胞移植后。卫生（隔离）和治疗（利巴韦林、免疫球蛋白、帕利珠单抗）措施的有效性取决于高度的怀疑指数以及通过抗原检测、聚合酶链反应（PCR）和/或培养进行快速诊断确认。资源分配需要根据已知或估计的并发症风险对措施进行分层。
